HBV

LP10 is a non-azole inhibitor targeting CYP51, showing potent activity against Hepatitis B Virus (HBV). This compound disrupts viral replication by inhibiting 14α-demethylation, which is critical for cholesterol biosynthesis in the virus. LP10 is useful for studying HBV infection mechanisms and evaluating antiviral strategies.

DVR-01 is a hepatitis B virus (HBV) inhibitor that exhibits antiviral activity in AML12HBV10 and HepDES19 cell lines, with EC50 values of 1.7 and 1.6 μM, respectively. This compound also demonstrates efficacy against drug-resistant HBV mutants, exhibiting EC50 values ranging from 2.403 to 3.273 μM. DVR-01 is suitable for research applications focused on HBV infection and associated diseases, contributing to the understanding of viral mechanisms and potential therapeutic interventions.

KKJ00626 is a potent inhibitor of Hepatitis B virus (HBV) with an IC50 of 0.12 to 0.23 μM. This compound targets the interaction between HBV core protein and the surface protein PreS region, effectively preventing the maturation and secretion of HBV particles. Its significant antiviral activity makes KKJ00626 a valuable tool for research in HBV therapeutics and virology studies.

HBV/HDV-IN-5 is a potent inhibitor targeting hepatitis B virus (HBV) and hepatitis D virus (HDV). This compound exhibits significant antiviral activity, making it valuable for research focused on viral hepatitis. HBV/HDV-IN-5 is primarily utilized in studies exploring antiviral therapies and the mechanisms underlying HBV and HDV infections.

Morphothiadin mesylate is a potent inhibitor of Hepatitis B Virus (HBV) replication, targeting both wild-type and Adefovir-resistant strains. With an IC50 value of 12 nM, it demonstrates significant antiviral activity. This compound is useful for research applications focused on HBV pathogenesis and the development of antiviral therapeutic strategies.

Coclauril is a potent inhibitor of Hepatitis B virus (HBV) replication, acting primarily on hepatocytes. It demonstrates antiviral activity in human hepatoblastoma cell lines, with an EC50 value of 7.6 μg/mL. Coclauril is utilized in research to explore therapeutic strategies against HBV and to study the mechanisms of viral replication inhibition.

BAY39-5493 is a non-nucleoside inhibitor targeting hepatitis B virus (HBV) replication. It exerts its biological activity by blocking the formation of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.03 μM against HBV in stably transfected HepG2.2.15 cells, BAY39-5493 serves as a valuable tool for research in the field of antiviral therapeutics and HBV biology.

BAY38-7690 is a non-nucleoside inhibitor that specifically targets hepatitis B virus (HBV) replication. It functions by obstructing the assembly of viral core particles, thereby inhibiting viral DNA replication. With an IC50 value of 0.15 μM in stably transfected HepG2.2.15 cells, BAY38-7690 is an important tool for investigating HBV biology and evaluating potential therapeutic strategies against hepatitis B virus infections.

Personalised postprandial-targeting is an HBV inhibitor that modulates water-heme interactions, specifically targeting low-spin cytochrome P450 complexes. This reagent effectively preserves the axial water ligands of CYP2C9, even when inhibitors are present, enabling advanced studies of enzyme dynamics. Additionally, it facilitates the observation of hydrogen atoms in the axial water ligands through EPR spectroscopy, offering valuable insights into the active site of the enzyme, making it a critical tool for research in enzymology and drug development.

GS-8873 TFA is a potent inhibitor of hepatitis B virus (HBV) surface antigen (HBsAg) production, exhibiting an EC50 value of 4 nM. This orally bioavailable compound demonstrates favorable pharmacokinetic properties in rodent models and metabolic stability in human hepatocytes. Notably, GS-8873 TFA has been associated with neurofunctional deficits in both rats and cynomolgus monkeys, making it a valuable tool for research in HBV therapies and associated neurological effects.

FMAU is a nucleoside analog that primarily inhibits the replication of hepatitis B virus (HBV) and Epstein-Barr virus (EBV). Once phosphorylated by human thymidine kinase, FMAU is incorporated into DNA, serving as a valuable marker for cell proliferation. Its research applications extend to studies on herpes simplex virus infection and various cancer types.

1793065-08-3 (R-isomer) 2093044-32-5 (S-isomer) 1092970-12-1 (racemic) 1646361-04-7 (mesylate)

Entecavir (SQ 34676; BMS 200475) is a potent and selective inhibitor of HBV, with an EC50 of 3.75 nM in HepG2 cell.

Bay 41-4109 less active enantiomer shows less activity than Bay 41-4109. BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

RG7834 (RO 7020322) is a highly selective and orally bioavailable HBV inhibitor, potently inhibits HBV antigens (both HBsAg and HBeAg) and HBV DNA, with IC50s of 2.8, 2.6, and 3.2 nM, respectively, in dHepaRG Cells.

Merimepodib is a noncompetitive and oral inhibitor of inosine monophosphate dehydrogenase (IMPDH) with broad spectrum antiviral activities.

AB-423 is an inhibitor of HBV capsid assembly, and potent inhibits HBV replication with EC50/EC90 of 0.08-0.27 μM/0.33-1.32 μM in cells.

BAY 41-4109 is a potent inhibitor of human hepatitis B virus (HBV) with an IC50 of 53 nM.

Bersacapavir is an HBV capsid assembly modulator that targets hepatitis B virus (HBV) replication. It exhibits a dual mechanism of action by forming complete genome-free empty capsids and inhibiting the de novo synthesis of covalently closed circular DNA (cccDNA). This compound is valuable for research applications focusing on HBV infection and the development of antiviral therapies.

β-Thujaplicinol is a potent inhibitor of hepatitis B virus (HBV) ribonuclease H, showing inhibitory effects on HBV genotypes D and H with IC50 values of 5.9 and 2.3 μM, respectively. Its primary mechanism involves disrupting the enzymatic activity of HBV RNase H, making it a valuable tool for researching HBV replication and pathogenesis. This compound is suitable for studies focused on antiviral development and the therapeutic targeting of HBV.

ALG-000184 is an orally bioavailable inhibitor targeting hepatitis B virus (HBV). It functions as a prodrug to ALG-001075 and effectively reduces HBV DNA production in liver cells. This compound is intended for research applications in chronic hepatitis B studies, facilitating investigations into therapeutic strategies against HBV infection.

AT-130 is a phenylpropenamide derivative that serves as a potent non-nucleoside inhibitor of hepatitis B virus (HBV) replication. It effectively inhibits viral DNA synthesis, exhibiting an EC50 of 0.13 μM against both wild-type and mutant strains of HBV. AT-130 demonstrates significant anti-HBV activity in hepatoma cell lines, making it a valuable tool for research focused on HBV infection and treatment strategies.

HBV-IN-4 is a phthalazinone derivative that functions as a potent inhibitor of HBV DNA replication, exhibiting an IC50 value of 14 nM. This compound effectively induces the formation of genome-free capsids, demonstrating substantial anti-HBV activity. Its applications include research into therapeutic strategies for hepatitis B virus infections.

Alisol F 24-acetate is a triterpenoid compound that targets Hepatitis B Virus (HBV) by inhibiting the secretion of HBV surface antigens HBsAg and HBeAg, with respective IC50 values of 7.7 µM and 5.1 µM. This compound also exhibits proapoptotic activity, making it a valuable agent for cancer research applications. Its role in regulating viral antigen secretion positions it as a potential therapeutic candidate in HBV-related studies.

HBV-IN-23 is a potent inhibitor of Hepatitis B virus (HBV) DNA replication with an IC50 of 0.58 μM. This compound effectively inhibits HBV replication across both sensitive and resistant strains. Additionally, HBV-IN-23 demonstrates anti-hepatocellular carcinoma activity by inducing apoptosis in HepG2 cells, making it a valuable tool for research into HBV and related hepatic conditions.

HBV-IN-48 is a potent inhibitor of Hepatitis B Virus (HBV) with demonstrated antiviral activity. It effectively reduces viral replication in HepDE19 cells, achieving an EC50 value of 0.005 μM. Additionally, HBV-IN-48 has shown the ability to lower serum HBV DNA levels in mouse models, making it a valuable tool for studying HBV infections and potential therapeutic interventions.

LB80317 is an active metabolite of LB80380 that functions as a potent inhibitor of HBV DNA synthesis, exhibiting an EC50 of 0.5 μM. This compound demonstrates antiviral activity, making it a promising candidate for the treatment of chronic hepatitis B. Its ability to inhibit viral replication supports its potential utility in HBV research and therapeutic applications.

HBV-IN-21 is a potent inhibitor of hepatitis B virus (HBV) DNA replication, exhibiting an IC50 of 2.2 µM. This compound demonstrates a strong interaction with the HBV core capsid protein, characterized by a dissociation constant (KD) of 60.0 μM. HBV-IN-21 is suited for research applications focused on antiviral drug development and elucidation of HBV replication mechanisms.

HBV-IN-22 is a potent inhibitor of Hepatitis B Virus (HBV) DNA replication, demonstrating IC50 values of 0.71 μM against wild-type strains and 0.84 μM against resistant strains. This compound is valuable for research focused on antiviral drug development and understanding HBV resistance mechanisms, making it a critical tool in the study of Hepatitis B therapeutics.

L-2'-Fd4C is an L-nucleoside analogue that acts as an inhibitor of both human immunodeficiency virus (HIV) and hepatitis B virus (HBV). This compound exhibits potent antiviral activity, making it valuable for research focused on the treatment and understanding of these viral infections. Its unique mechanism of action may provide insights into the development of novel therapeutic strategies against HIV and HBV.

HBV-IN-53 is an inhibitor of Hepatitis B virus (HBV) that effectively reduces serum levels of HBV DNA. Its potent antiviral activity makes it a valuable tool for research in HBV therapeutics. Additionally, HBV-IN-53 has been shown to exhibit an additive inhibitory effect when combined with Tenofovir disoproxil fumarate, highlighting its potential for use in combination therapy studies.

Telbivudine is an orally active thymidine nucleoside analog that acts as an inhibitor of hepatitis B virus (HBV) replication. Its potent antiviral activity makes it valuable in the study of HBV-related pathologies and the development of antiviral therapies. This compound serves as a significant tool for researchers investigating HBV dynamics and therapeutic interventions.

Catalpol, an iridoid glycoside derived from Rehmannia glutinosa, primarily targets hepatitis B virus (HBV) inhibition. It exhibits a broad range of biological activities including neuroprotection, hypoglycemic effects, anti-inflammatory properties, and antioxidant effects. Additionally, Catalpol demonstrates potential in anti-cancer and anti-spasmodic applications, making it valuable for various research contexts focusing on viral infections and related therapeutic interventions.